Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 11,433 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting No phase listed Observational

Liver Disease in Urea Cycle Disorders

NCT04612764
Conditions
Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency, Citrullinemia 1, ARGI Deficiency, ASL Deficiency, Argininosuccinic Aciduria, ASS Deficiency, Hyperargininemia
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Philadelphia, Pennsylvania + 2 more
Conditions
Multiple Myeloma
Interventions
CC-92480, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib, Elotuzumab, Isatuximab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
Denver, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Conditions
Crohn's Disease (CD)
Interventions
ABT-494
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
27
States / cities
La Jolla, California • San Francisco, California • Gainesville, Florida + 22 more
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Flumazenil Reversal of Oral Triazolam

NCT00695630
Conditions
Dental Anxiety
Interventions
Flumazenil, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Type 1 Diabetes Mellitus
Interventions
Liraglutide, Golimumab
Drug
Lead sponsor
Carla Greenbaum, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Idaho Falls, Idaho • Seattle, Washington
Conditions
Asthma
Interventions
Placebo, FP 100mcg, FP 250mcg, FP 500mcg, FSC 100/50mcg, FSC 250/50mcg, FSC500/50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 43 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Refractory Breast Carcinoma
Interventions
Alpha-tocopheryloxyacetic Acid, Trastuzumab
Drug · Biological
Lead sponsor
Veana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
iSABR, 25 Gray in 1 fraction for small peripheral tumors, iSABR, 50 Gray in 4 fractions for medium peripheral tumors, iSABR, 54 Gray in 3 fractions for large peripheral tumors, iSABR, 40 Gray in 4 fractions for small central tumors, iSABR, 50 Gray in 4 fractions for medium central tumors, iSABR, 60 Gray in 8 fractions for large central tumors
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Stanford, California • Seattle, Washington
Conditions
Spinal Cord Injuries
Interventions
Transcutaneous Spinal Cord Stimulation, Sham Stimulation
Device
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting Not applicable Interventional Results available

Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones

NCT02028559
Conditions
Kidney Stones, Nephrolithiasis, Urolithiasis
Interventions
Propulse 1 with C5-2 probe, Propulse 1 with SC-X probe
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
2
States / cities
Seattle, Washington
Conditions
Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases, Diabetes Melletus, Type 1, Nutritional and Metabolic Diseases, Combination Therapy
Interventions
AMX0035, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 69 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Neuroblastoma
Interventions
aldesleukin, therapeutic autologous lymphocytes, chemotherapy, ganciclovir
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Completed No phase listed Observational

Life After Pediatric Sepsis Evaluation

NCT01415180
Conditions
Septic Shock
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 18 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Conditions
Post-Operative Atrial Fibrillation
Interventions
AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy
Device · Drug
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
22
States / cities
San Diego, California • Stanford, California • Orlando, Florida + 15 more
Conditions
Prostate Cancer
Interventions
Plenaxis
Drug
Lead sponsor
PRAECIS Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
60
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more
Terminated Not applicable Interventional Results available

Deep Brain Stimulation for Major Depressive Disorder

NCT00617162
Conditions
Depressive Disorder, Major, Unipolar Depression
Interventions
Deep Brain Stimulation, Libra Deep Brain Stimulation System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
21 Years to 70 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
11
States / cities
Stanford, California • Chicago, Illinois • Worcester, Massachusetts + 8 more
Conditions
Carpal Tunnel Syndrome
Interventions
Early Carpal Tunnel Release for Mild or Moderate CTS, MR Nerve Imaging for CTS
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Hemostasis, Oral Contraceptive
Interventions
91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
Drug
Lead sponsor
Teva Women's Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more
Conditions
Hodgkin Lymphoma
Interventions
brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, G-CSF, nivolumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
12 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
55
States / cities
Fountain Valley, California • Aurora, Colorado • Colorado Springs, Colorado + 48 more
Conditions
Substance-Related Disorders, Hepatitis
Interventions
Pegylated Interferon
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
15 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
Interventions
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Drug
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Not listed
Enrollment
99,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2041
U.S. locations
142
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more
Conditions
Cystic Fibrosis
Interventions
TEZ, IVA, VX-440, Matched Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more